Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024
Protalix BioTherapeutics (NYSE American: PLX) has announced that it will release its financial results for the second quarter of 2024 on August 14, 2024. The company, which specializes in developing recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system, will also provide a business and clinical update during a conference call with investors.
The conference call is scheduled for 8:30 a.m. EDT on August 14, 2024. Investors can join via toll-free numbers for US and Israeli participants, or through an international line. A webcast of the call will also be available, and a replay will be accessible for two weeks on the company's website.
Protalix BioTherapeutics (NYSE American: PLX) ha annunciato che pubblicherà i suoi risultati finanziari per il secondo trimestre del 2024 il 14 agosto 2024. L'azienda, specializzata nello sviluppo di proteine terapeutiche ricombinanti utilizzando il suo sistema proprietario ProCellEx® basato su cellule vegetali, fornirà anche un aggiornamento sulle attività e sulla clinica durante una conferenza telefonica con gli investitori.
La conferenza telefonica è programmata per le 8:30 a.m. EDT del 14 agosto 2024. Gli investitori possono partecipare tramite numeri verdi per i partecipanti statunitensi e israeliani, o tramite una linea internazionale. Sarà disponibile anche una web diretta della chiamata, e una registrazione sarà accessibile per due settimane sul sito web dell'azienda.
Protalix BioTherapeutics (NYSE American: PLX) ha anunciado que publicará sus resultados financieros para el segundo trimestre de 2024 el 14 de agosto de 2024. La compañía, que se especializa en el desarrollo de proteínas terapéuticas recombinantes utilizando su sistema de expresión de proteínas a base de células vegetales ProCellEx®, también proporcionará una actualización sobre sus actividades comerciales y clínicas durante una conferencia telefónica con los inversores.
La conferencia telefónica está programada para las 8:30 a.m. EDT del 14 de agosto de 2024. Los inversores pueden unirse a través de números gratuitos para participantes de EE. UU. e Israel, o a través de una línea internacional. También estará disponible una transmisión en vivo de la llamada, y una repetición será accesible durante dos semanas en el sitio web de la compañía.
Protalix BioTherapeutics (NYSE American: PLX)는 2024년 2분기 재무 결과를 2024년 8월 14일에 발표할 것이라고 발표했습니다. 이 회사는 독자적인 ProCellEx® 식물 세포 기반 단백질 발현 시스템을 사용하여 재조합 치료 단백질을 개발하는 데 전문화되어 있으며, 투자자와의 전화 회의 중에 사업 및 임상 업데이트를 제공할 예정입니다.
전화 회의는 2024년 8월 14일 오전 8:30 EDT에 예정되어 있습니다. 투자자는 미국 및 이스라엘 참가자를 위한 무료 전화번호로 참여하거나 국제 전화로 참여할 수 있습니다. 회의의 웹캐스트도 제공될 예정이며, 회사 웹사이트에서 2주 동안 반복 청취가 가능합니다.
Protalix BioTherapeutics (NYSE American: PLX) a annoncé qu'elle publiera ses résultats financiers pour le deuxième trimestre de 2024 le 14 août 2024. L'entreprise, qui se spécialise dans le développement de protéines thérapeutiques recombinantes utilisant son système d'expression protéique à base de cellules végétales ProCellEx®, fournira également une mise à jour commerciale et clinique lors d'une conférence téléphonique avec les investisseurs.
La conférence téléphonique est prévue pour le 14 août 2024 à 8 h 30 EDT. Les investisseurs peuvent rejoindre via des numéros gratuits pour les participants américains et israéliens, ou par le biais d'une ligne internationale. Une diffusion en direct de l'appel sera également disponible et un replay sera accessible pendant deux semaines sur le site web de l'entreprise.
Protalix BioTherapeutics (NYSE American: PLX) hat angekündigt, dass es am 14. August 2024 seine finanziellen Ergebnisse für das zweite Quartal 2024 veröffentlichen wird. Das Unternehmen, das sich auf die Entwicklung rekombinanter therapeutischer Proteine mithilfe seines proprietären ProCellEx® pflanzenzellbasierten Proteinexpression-Systems spezialisiert hat, wird auch während einer Telefonkonferenz mit Investoren ein Update zu Geschäft und Klinik geben.
Die Telefonkonferenz ist für den 14. August 2024 um 8:30 a.m. EDT angesetzt. Investoren können über gebührenfreie Nummern für US-amerikanische und israelische Teilnehmer oder über eine internationale Leitung teilnehmen. Es wird auch eine Webcast der Konferenz verfügbar sein, und eine Aufzeichnung wird zwei Wochen lang auf der Unternehmenswebsite zugänglich sein.
- None.
- None.
Company to host conference call and webcast at 8:30 a.m. EDT
CARMIEL,
Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments.
Conference Call Details:
Date: Wednesday, August 14, 2024
Time: 8:30 a.m. Eastern Daylight Time (EDT)
Toll Free: 1-877-423-9813
International: 1-201-689-8573
Israeli Toll Free: 1-809-406-247
Conference ID: 13747744
Call me™: https://tinyurl.com/2n9fhumh
The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.
Webcast Details:
Company Link: https://ir.protalix.com/news-events/events
Webcast Link: https://tinyurl.com/yb6bu7vs
Conference ID: 13747744
Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others.
Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-second-quarter-2024-financial-and-business-results-on-august-14-2024-302216497.html
SOURCE Protalix BioTherapeutics, Inc.
FAQ
When will Protalix BioTherapeutics (PLX) release its Q2 2024 financial results?
What time is the Protalix BioTherapeutics (PLX) Q2 2024 earnings call scheduled for?
How can investors access the Protalix BioTherapeutics (PLX) Q2 2024 earnings call?
What is Protalix BioTherapeutics' (PLX) main focus as a biopharmaceutical company?
